Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination

• Published in: Journal for immunotherapy of cancer Vol. 10; no. 10; p. e005248
• Main Authors: van der Woude, Lieke L, Gorris, Mark A J, Wortel, Inge M N, Creemers, Jeroen H A, Verrijp, Kiek, Monkhorst, Kim, Grünberg, Katrien, van den Heuvel, Michel M, Textor, Johannes, Figdor, Carl G, Piet, Berber, Theelen, Willemijn S M E, de Vries, I Jolanda M
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.10.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Antibodies; Antibodies, Monoclonal, Humanized; Antigens; Apoptosis; Automation; Basic Tumor Immunology; Biopsy; Cancer; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Cell death; Cloning; Cytokeratin; Forkhead Transcription Factors; Humans; Immunology; Immunotherapy; Keratins; Ligands; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Metastasis; Monoclonal antibodies; Patients; programmed cell death 1 receptor; Radiation therapy; radiotherapy; Response rates; Targeted cancer therapy; Tumor Microenvironment; Tumors; radiotherapy; programmed cell death 1 receptor; tumor microenvironment; immunotherapy
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2022-005248

BackgroundImmunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to increase clinical benefit. The PEMBRO-RT trial combined the therapeutic programmed cell death 1 (PD-1) antibody pembrolizumab with stereotactic body radiation therapy (SBRT) to increase the overall response rate and study the effects on the tumor microenvironment (TME).MethodsHere, immune infiltrates in the TME of patients included in the PEMBRO-RT trial were investigated. Tumor biopsies of patients treated with pembrolizumab alone or combined with SBRT (a biopsy of the non-irradiated site) at baseline and during treatment were stained with multiplex immunofluorescence for CD3, CD8, CD20, CD103 and FoxP3 for lymphocytes, pan-cytokeratin for tumors, and HLA-ABC expression was determined.ResultsThe total number of lymphocytes increased significantly after 6 weeks of treatment in the anti-PD-1 group (fold change: 1.87, 95% CI: 1.06 to 3.29) and the anti-PD-1+SBRT group (fold change: 2.29, 95% CI: 1.46 to 3.60). The combination of SBRT and anti-PD-1 induced a 4.87-fold increase (95% CI: 2.45 to 9.68) in CD103+ cytotoxic T-cells 6 weeks on treatment and a 2.56-fold increase (95% CI: 1.03 to 6.36) after anti-PD-1 therapy alone. Responders had a significantly higher number of lymphocytes at baseline than non-responders (fold difference 1.85, 95% CI: 1.04 to 3.29 for anti-PD-1 and fold change 1.93, 95% CI: 1.08 to 3.44 for anti-PD-1+SBRT).ConclusionThis explorative study shows that that lymphocyte infiltration in general, instead of the infiltration of a specific lymphocyte subset, is associated with response to therapy in patients with NSCLC.Furthermore, anti-PD-1+SBRT combination therapy induces an immunological abscopal effect in the TME represented by a superior infiltration of cytotoxic T cells as compared with anti-PD-1 monotherapy.